This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of +40.00% and +7.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -51.43% and 66.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
by Zacks Equity Research
Werewolf Therapeutics (HOWL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira (PCRX) Tops Q4 Earnings Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 5.81% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
MiMedx (MDXG) Q4 Earnings Meet Estimates
by Zacks Equity Research
MiMedx (MDXG) delivered earnings and revenue surprises of 0% and 6.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Pharmaceutical (BMRN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 26.03% and 4.97%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arvinas (ARVN) delivered earnings and revenue surprises of 41.12% and 4.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer (SEER) delivered earnings and revenue surprises of -17.24% and 19.64%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics (HOWL) delivered earnings and revenue surprises of -13.16% and 42.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
SpringWorks Therapeutics (SWTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of 51.79% and 73.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
by Zacks Equity Research
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
by Zacks Equity Research
The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 23.26% and 45.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of 30% and 145.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?
by Zacks Equity Research
Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 65.85% and 164.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 2.63% and 25.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 0% and 14.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for July 26th
by Zacks Equity Research
ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.
Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?
by Zacks Equity Research
In its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up for the declining Humira sales following the loss of U.S. exclusivity.
Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing
by Zacks Equity Research
Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional marketing authorization.
Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal
by Zacks Equity Research
Interim data from a late-stage study, evaluating Merck's (MRK) Keytruda as a combination therapy, met one of its primary endpoints of progression-free survival.
Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 30.61% and 46.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?